Literature DB >> 2267481

Bacteremia due to Escherichia coli: a study of 861 episodes.

W R Gransden1, S J Eykyn, I Phillips, B Rowe.   

Abstract

Escherichia coli accounted for 861 (23.9%) of 3,605 episodes of bacteremia in an 18-year prospective survey at St. Thomas' Hospital, a proportion that changed little during the survey. The most common focus of infection leading to nosocomial and community-acquired bacteremia due to E. coli was the urinary tract. Twenty-six percent of adult female patients with E. coli bacteremia resulting from a urinary tract infection were diabetic. The O antigen serotypes identified most often were O6, O2, O1, O4, O15, and O75; the multiply resistant O15 serotype of E. coli was implicated in a community outbreak of urinary tract infection. Ampicillin resistance in strains causing community-acquired infection increased to the same level as that of strains causing nosocomial infection (almost 50%). The overall mortality was 20.7% and was greater in the presence of shock (52.4% vs. 15.3%). Death due to infection occurred in 2.6% and 10.3%, respectively, of cases with urinary tract and non-urinary tract foci. The adverse influence of inappropriate initial therapy on outcome was more marked in the latter half of the study.

Entities:  

Mesh:

Year:  1990        PMID: 2267481     DOI: 10.1093/clinids/12.6.1008

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  39 in total

Review 1.  How do you choose antibiotic treatment?

Authors:  L Leibovici; I Shraga; S Andreassen
Journal:  BMJ       Date:  1999-06-12

2.  A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Stacy A Genagon; Ulrike MacDonald; John J Cope; Bruce A Davidson; Brian Johnston; James R Johnson
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

3.  The Escherichia coli K5 capsule is not synthesized in a protected compartment within the cytoplasm.

Authors:  Thomas Hudson; Marie Goldrick; Ian S Roberts
Journal:  J Bacteriol       Date:  2008-12-12       Impact factor: 3.490

4.  Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product.

Authors:  M Trautmann; T K Held; M Susa; M A Karajan; A Wulf; A S Cross; R Marre
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

5.  Diagnosis of E. coli tricuspid valve endocarditis: a case report.

Authors:  Takahiko Tsutsumi; Eiji Hiraoka; Kenji Kanazawa; Hozuka Akita; Lawrence J Eron
Journal:  Hawaii Med J       Date:  2010-12

6.  Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide.

Authors:  Jaione Valle; Sandra Da Re; Nelly Henry; Thierry Fontaine; Damien Balestrino; Patricia Latour-Lambert; Jean-Marc Ghigo
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-07       Impact factor: 11.205

7.  O-antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections.

Authors:  M Trautmann; M Ruhnke; T Rukavina; T K Held; A S Cross; R Marre; C Whitfield
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

8.  Predisposing conditions and pathogens in bacteremia in hospitalized children.

Authors:  R Berner; R F Schumacher; S Bartelt; J Forster; M Brandis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

9.  A 7-year study of bloodstream infections in an English children's hospital.

Authors:  James W Gray
Journal:  Eur J Pediatr       Date:  2004-07-06       Impact factor: 3.183

10.  Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice.

Authors:  H Frasa; B Benaissa-Trouw; L Tavares; K van Kessel; M Poppelier; K Kraaijeveld; J Verhoef
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.